DSpace university logo mark
詳細検索
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > 130 病院 > 130 学術雑誌論文 >

Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: Comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.


ファイル 記述 サイズフォーマット
JBS77_418.pdf534.25 kBAdobe PDF本文ファイル

タイトル: Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: Comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.
著者: Kawashiri, Shin-Ya / Kawakami, Atsushi / Ueki, Yukitaka / Imazato, Takahiro / Iwamoto, Naoki / Fujikawa, Keita / Aramaki, Toshiyuki / Tamai, Mami / Nakamura, Hideki / Origuchi, Tomoki / Ida, Hiroaki / Eguchi, Katsumi
発行日: 2010年10月
出版者: Elsevier Masson SAS
引用: Joint Bone Spine, 77(5), pp.418-420; 2010
抄録: OBJECTIVE: The aim of this study was to evaluate whether serum COMP can estimate the therapeutic response of RA after 6 months of treatment with etanercept. METHODS: Forty-five RA patients receiving 25mg of etanercept twice a week for 6 months were registered in this prospective observational study. Clinical response to the therapy was evaluated by DAS 28. Laboratory variables- COMP, CRP, ESR, IgM-RF, MMP-3, and anti-CCP Ab -were assessed at baseline and after 6 months of treatment. We assessed the correlations between serum COMP and other variables and whether serum COMP is associated with DAS28 remission. RESULTS: Serum COMP correlated with DAS28-ESR (p<0.05, r=0.40) at baseline. At 6 months of etanercept treatment, 10 patients entered remission (DAS28-ESR<2.6) whereas the other 35 patients did not (DAS28-ESR>2.6). The decrement of serum COMP at 6 months was significant in the remission group (N=10) but not in the non-remission group (N=35). On the other hand, CRP, ESR and MMP-3 decreased at 6 months regardless of remission status. IgM-RF titer as well as anti-CCP Ab titer did not differ at 6 months. CONCLUSIONS: Serum COMP at baseline reflects clinical disease activity of RA. Serum COMP is a valuable serologic marker to identify the subset of RA patients achieving remission during treatment with etanercept.
キーワード: Cartilage oligomeric matrix protein / Etanercept / Rheumatoid arthritis
URI: http://hdl.handle.net/10069/24324
ISSN: 1297319X
DOI: 10.1016/j.jbspin.2010.01.016
PubMed ID: 20864374
権利: Copyright © 2010 Published by Elsevier Masson SAS
資料タイプ: Journal Article
原稿種類: author
出現コレクション:130 学術雑誌論文

引用URI : http://hdl.handle.net/10069/24324

このリポジトリに保管されている文献はすべて著作権により保護されています。
印刷やダウンロード等データの複製は、調査研究・教育または学習を目的とする場合に限定されます。

 

Valid XHTML 1.0! Copyright © 2006-2015 長崎大学附属図書館 - お問い合わせ Powerd by DSpace